Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 9

Submit an article Journal homepage

Views

CrossRef citations to date

Altmetric

Reviews

Angiotensin II receptor blockers in the prevention of atrial fibrillation

Silvia Barra Antonio Cardarelli Hospital, Cardiology Unit, Via Antonio Cardarelli 9, 80128 Naples, Italy +39 081 7472808; +39 081 7472810; [email protected]

Nunzia Silvestri Antonio Cardarelli Hospital, Cardiology Unit, Via Antonio Cardarelli 9, 80128 Naples, Italy +39 081 7472808; +39 081 7472810; [email protected]

, MD,

Giancarlo Vitagliano Antonio Cardarelli Hospital, Cardiology Unit, Via Antonio Cardarelli 9, 80128 Naples, Italy +39 081 7472808; +39 081 7472810; [email protected]

, MD,

Alfredo Madrid Antonio Cardarelli Hospital, Cardiology Unit, Via Antonio Cardarelli 9, 80128 Naples, Italy +39 081 7472808; +39 081 7472810; [email protected]

, MD &

Giovanni Gaeta Antonio Cardarelli Hospital, Cardiology Unit, Via Antonio Cardarelli 9, 80128 Naples, Italy +39 081 7472808; +39 081 7472810; [email protected]

, MD FESC FAHA

Pages 1395-1411 | Published online: 26 May 2009

Cite this article
https://doi.org/10.1517/14656560902973736

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Benjamin EJ, Chen PS, Bild DE, et al. Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop. Circulation 2009;119:606-18
PubMed Web of Science ®Google Scholar
Fuster V, Rydén LE, Cannom DS, et al. Task Force on Practice Guidelines, American College of Cardiology/American Heart Association; Committee for Practice Guidelines, European Society of Cardiology; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030
PubMed Web of Science ®Google Scholar
Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-20
PubMed Web of Science ®Google Scholar
Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006;166:719-28
PubMed Web of Science ®Google Scholar
Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80
PubMed Web of Science ®Google Scholar
Vermes E, Tardif J-C, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with ventricular dysfunction: insight from the studies of left ventricular dysfunction (SOLVD) trials. Circulation 2002;107:2926-31
Web of Science ®Google Scholar
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5
PubMed Web of Science ®Google Scholar
Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-41
PubMed Web of Science ®Google Scholar
Savelieva I, Camm J. Update on atrial fibrillation: part I. Clin Cardiol 2008;31:55-62
PubMed Web of Science ®Google Scholar
Lip GY, Tean KN, Dunn FG. Treatment of atrial fibrillation in a district general hospital. Br Heart J 1994;71:92-5
PubMedGoogle Scholar
Santini M, De Ferrari GM, Pandozi C, et al.; FIRE Investigators. Atrial fibrillation requiring urgent medical care. Approach and outcome in the various departments of admission. Data from the atrial fibrillation/flutter italian registry (FIRE). Ital Heart J 2004;5:205-13
PubMedGoogle Scholar
Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84
PubMed Web of Science ®Google Scholar
Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
PubMed Web of Science ®Google Scholar
Wolf PA, Dawber TR, Thomas HE Jr, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978;28:973-7
PubMed Web of Science ®Google Scholar
Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart 2003;89:939-43
PubMed Web of Science ®Google Scholar
Freestone B, Lip GYH. Epidemiology and costs of cardiac arrhythmias. In: Lip GYH, Godtfredson J, editors, Cardiac arrhythmias: a clinical approach. Edinburgh: Mosby, 2003. p. 3-24
Google Scholar
Lévy S, Breithardt G, Campbell RW, et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J 1998;19:1294-320
PubMed Web of Science ®Google Scholar
Lévy S, Novella P, Ricard P, Paganelli F. Paroxysmal atrial fibrillation: a need for a classification. J Cardiovasc Electrophysiol 1995;6:75-7
PubMed Web of Science ®Google Scholar
Gallagher MM, Camm J. Classification of atrial fibrillation. Am J Cardiol 1998;82:18N-28N
PubMed Web of Science ®Google Scholar
Lévy S. Classification system of atrial fibrillation. Curr Opin Cardiol 2000;15:54-7
PubMed Web of Science ®Google Scholar
Evans W, Swann P. Lone auricular fibrillation. Br Heart J 1954;16:189-94
PubMedGoogle Scholar
Kopecky SL, Gersh BJ, McGoon MD, et al. Lone atrial fibrillation in elderly persons: a marker for cardiovascular risk. Arch Intern Med 1999;159:1118-22
PubMed Web of Science ®Google Scholar
Allessie MA, Konings K, Kirchhof C, Wijffels M. Electrophysiologic mechanisms of perpetuation of atrial fibrillation. Am J Cardiol 1996;77:10A-23A
Google Scholar
Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J 1964;67:200-20
PubMed Web of Science ®Google Scholar
Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68
PubMed Web of Science ®Google Scholar
Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 1997;96:3157-63
PubMed Web of Science ®Google Scholar
Brundel BJJM, Henning RH, Kampinga HH, et al. Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res 2002;54:315-24
PubMed Web of Science ®Google Scholar
Zankov DP, Omatsu-Kanbe M, Isono T, et al. Angiotensin II potentiates the slow component of delayed rectifier K + current via the AT-1 receptor in guinea pig atrial myocytes. Circulation 2006;113:1278-86
PubMed Web of Science ®Google Scholar
Doronin SV, Potapova IA, Lu Z, Cohen IS. Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization. J Biol Chem 2004;279:48231-7
PubMed Web of Science ®Google Scholar
Zhang TT, Takimoto K, Stewart AF, et al. Indipendent regulation of cardiac Kv4.3 potassium channel expression by angiotensin II and phenylephrine. Circ Res 2000;88:476-82
Web of Science ®Google Scholar
Pueyo ME, Gonzalez W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000;20:645-51
PubMed Web of Science ®Google Scholar
Schieffer B, Schieffer E, Hilfiker-Kleiner D, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaque: potential implications for inflammation and plaque instability. Circulation 2000;101:1372-8
PubMed Web of Science ®Google Scholar
Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-4
PubMed Web of Science ®Google Scholar
Li D, Saldeen T, Romeo F, Mehta J. Oxidized LDL upregulates angiotensin II type receptor expression in cultured human coronary artery endothelial cells. Circulation 2002;102:1970-6
Web of Science ®Google Scholar
Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-17
PubMed Web of Science ®Google Scholar
Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation: time course and mechanisms. Circulation 1996;94:1968-974
Web of Science ®Google Scholar
Kumagai K, Nakashima H, Urata H, et al. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodelling in atrial fibrillation. J Am Coll Cardiol 2003;41:21972204
Google Scholar
Tsai CT, Lai LP, Lin JL, et al. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004;109:1640-6
PubMed Web of Science ®Google Scholar
Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77
PubMed Web of Science ®Google Scholar
Everett TH 4th, Li H, Mangrum JM, et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation. Circulation 2000;102:1454-60
PubMed Web of Science ®Google Scholar
Nakashima H, Kumagai K. Reverse-remodeling effects of angiotensin II type 1 receptor blocker in a canine atrial fibrillation model. Circ J 2007;71:1977-82
PubMed Web of Science ®Google Scholar
Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006;27:136-49
PubMed Web of Science ®Google Scholar
Libby P, Simon DI. Inflammation and thrombosis. The clot thickens. Circulation 2001;103:1718-20
PubMed Web of Science ®Google Scholar
Vaughan DE, Lazos SA, Tong K. Angiotensis II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001
PubMed Web of Science ®Google Scholar
Nakamura S, Nakamura I, Ma L, et al. Plasminogen activator inhibitor-1 expression is regulated by the angiotensin type I receptor in vivo. Kidney Int 2000;58:251-9
PubMed Web of Science ®Google Scholar
Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004;5:114-20
PubMed Web of Science ®Google Scholar
Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006;27:1841-6
PubMed Web of Science ®Google Scholar
Fazio G, Pizzuto C, Sutera L, et al. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart. Minerva Cardioangiol 2007;55:311-15
PubMedGoogle Scholar
Fogari R, Derosa G, Ferrari I, et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 2008;21:1034-9
PubMed Web of Science ®Google Scholar
Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensinconverting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999;353:611-16
PubMed Web of Science ®Google Scholar
Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-6
PubMed Web of Science ®Google Scholar
Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-19
PubMed Web of Science ®Google Scholar
Schmieder RE, Kjeldsen SE, Julius S, et al.; VALUE Trial Group. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 2008;26:403-11
PubMed Web of Science ®Google Scholar
Fogari R, Mugellini A, Destro M, et al. Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006;47:46-50
PubMed Web of Science ®Google Scholar
Fogari R, Zoppi A, Mugellini A, et al. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2008;51:217-22
PubMed Web of Science ®Google Scholar
Yusuf S, Teo KK, Pogue J, et al. N Engl J Med 2008;358:1547-59
PubMed Web of Science ®Google Scholar
Yusuf S, Teo K, Anderson C, et al; TRANSCEND (Telmisartan randomised assessment study in ACE intolerant subjects with cardiovascular disease) Investigators; Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008;372:1174-83
PubMed Web of Science ®Google Scholar
Salehian O, Healey J, Stambler B, et al.; HOPE Investigators. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation Study. Am Heart J 2007;154:403-6
PubMed Web of Science ®Google Scholar
Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75
PubMed Web of Science ®Google Scholar
Maggioni AP, Latini R, Carson PE, et al.; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-57
PubMed Web of Science ®Google Scholar
Pfeffer MA, Swedberg K, Granger CB, et al.; CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66
PubMed Web of Science ®Google Scholar
Yusuf S, Pfeffer MA, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003;362:777-81
PubMed Web of Science ®Google Scholar
Granger CB, McMurray JJ, Yusuf S, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6
PubMed Web of Science ®Google Scholar
McMurray JJ, Ostergren J, Swedberg K, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM added trial. Lancet 2003;362:767-71
PubMed Web of Science ®Google Scholar
Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Am Heart J 2006;152:86-92
PubMed Web of Science ®Google Scholar
Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9
PubMed Web of Science ®Google Scholar
Richter B, Derntl M, Marx M, et al. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation. Am Heart J 2007;153:113-19
PubMed Web of Science ®Google Scholar
Al Chekakie MO, Akar JG, Wang F, et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J Cardiovasc Electrophysiol 2007;18:942-6
PubMed Web of Science ®Google Scholar
Deneke T. ARBs, ACE-Is, or statins after catheter ablation of atrial fibrillation? J Cardiovasc Electrophysiol 2007;18:947-9
PubMed Web of Science ®Google Scholar
Madrid AH, Bueno MG, Rebollo JMG, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation a prospective and randomized study. Circulation 2002;106:331-6
PubMed Web of Science ®Google Scholar
Disertori M, Latini R, Maggioni AP, et al.; on behalf of the GISSI-AF Investigators. Rationale and design of the GISSI-Atrial Fibrillation trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence. J Cardiovasc Med 2006;7:29-38
Google Scholar
Pfeffer MA, McMurray JJ, Velazquez EJ, et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893-906
PubMed Web of Science ®Google Scholar
Køber L, Swedberg K, McMurray JJ, et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 2006;8:591-8
PubMed Web of Science ®Google Scholar
Sampson UK, Pfeffer MA, McMurray JJ, et al.; VALIANT Trial Investigators. Predictors of stroke in high-risk patients after acute myocardial infarction: insights from the VALIANT Trial. Eur Heart J 2007;28:685-91
PubMedGoogle Scholar
Lester SJ, Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research studies to determine left atrial size. Am J Cardiol 1999;84:829-32
PubMed Web of Science ®Google Scholar
Tsang TS, Abhayaratna WP, Barnes ME, et al. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? J Am Coll Cardiol 2006;47:1018-23
PubMed Web of Science ®Google Scholar
Neven K, Crijns H, Gorgels A. Atrial infarction: a neglected electrocardiographic sign with important clinical implications. J Cardiovasc Electrophysiol 2003;14:306-8
PubMed Web of Science ®Google Scholar
Cunningham KS, Chan KL, Veinot JP. Pathology of isolated atrial infarction: case report and review of the literature. Cardiovasc Pathol 2008;17:183-5
PubMed Web of Science ®Google Scholar
Nielsen FE, Andersen HH, Gram-Hansen P, et al. The relationship between ECG signs of atrial infarction and the development of supraventricular arrhythmias in patients with acute myocardial infarction. Am Heart J 1992;123:69-72
PubMed Web of Science ®Google Scholar
Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002;40:1636-44
PubMed Web of Science ®Google Scholar
Tziakas DN, Chalikias GK, Papanas N, et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace 2007;9:589-96
PubMed Web of Science ®Google Scholar
Fox CS, Parise H, D'Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2004;291:2851-5
PubMed Web of Science ®Google Scholar
Wiesfeld AC, Hemels ME, Van Tintelen JP, et al. Genetic aspects of atrial fibrillation. Cardiovasc Res 2005;67:414-18
PubMed Web of Science ®Google Scholar
Arnar DO, Thorvaldsson S, Manolio TA, et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J 2006;27:708-12
PubMed Web of Science ®Google Scholar
Brugada R, Tapscott T, Czernuszewicz GZ, et al. Identification of a genetic locus for familial atrial fibrillation. N Engl J Med 1997;336:905-11
PubMed Web of Science ®Google Scholar
Ellinor PT, Shin JT, Moore RK, et al. Locus for atrial fibrillation maps to chromosome 6q14-16. Circulation 2003;107:2880-3
PubMed Web of Science ®Google Scholar
Chen YH, Xu SJ, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science 2003;299:251-4
PubMed Web of Science ®Google Scholar
Yang Y, Xia M, Jin Q, et al. Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. Am J Hum Genet 2004;75:899-905
PubMed Web of Science ®Google Scholar
Oberti C, Wang L, Li L, et al. Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy. Circulation 2004;110:3753-59
PubMed Web of Science ®Google Scholar
Kato K, Oguri M, Hibino T, et al. Genetic factors for lone atrial fibrillation. Int J Mol Med 2007;19:933-9
PubMed Web of Science ®Google Scholar
Savelieva I, Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current antiarrhythmic drugs, investigational agents, and innovative approach. Europace 2008;10:647-65
PubMed Web of Science ®Google Scholar
Hohnloser SH, Crijns HJ, van Eickels M, et al.; ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Angiotensin II receptor blockers in the prevention of atrial fibrillation

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Angiotensin II receptor blockers in the prevention of atrial fibrillation

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date